3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Sarcoma
9
Rhabdomyosarcoma
7
Wilms Tumor
6
Malignant mesenchymal tumor
6
Ovarian Neoplasms
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Melanoma
2
Liposarcoma
2
Kidney Neoplasms
2
Hydatidiform Mole
2
Hemangiosarcoma
2
Hemangiopericytoma, Malignant
2
Fibrosarcoma
2
Desmoplastic Small Round Cell Tumor
2
Testicular Neoplasms
1
Teratoma, Ovarian
1
Sarcoma, Ewing
1
Rhabdoid Tumor
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms, Germ Cell and Embryonal
1
Lymphoma
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Gestational Trophoblastic Disease
1
Choriocarcinoma
1
Chondrosarcoma
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Blast Crisis
1
Beckwith-Wiedemann Syndrome
1
Interventions
Paclitaxel
5
Etoposide
4
Oxaliplatin
3
Ifosfamide
3
Granulocyte Colony-Stimulating Factor
3
Gemcitabine
3
Cyclophosphamide
3
Cisplatin
3
Carboplatin
3
ribociclib
2
fludarabine
2
etoposide phosphate
2
Stem Cell Transplantation
2
Sirolimus
2
Melphalan
2
Filgrastim
2
Everolimus
2
Busulfan
2
130-nm albumin-bound paclitaxel
2
trametinib
1
tozuleristide
1
sonidegib
1
ripretinib
1
pralsetinib
1
pembrolizumab
1
pegylated granulocyte colony-stimulating factor
1
pegfilgrastim
1
pazopanib
1
olaparib
1
interferon gamma-1b
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neoplasms, Germ Cell and Embryonal
×
Dactinomycin
×
Clear all
NCT06309732
2024-03-13
GAMEC-II
Queen Mary University of London
Phase 2
Completed
36 enrolled